Rare scene of wild pandas captured in Gansu s nature reserve By Ma Jingna in Gansu | chinadaily.com.cn | Updated: 2021-03-04 15:52 Share CLOSE
Recently, the Gansu Baishuijiang National Nature Reserve released a rare video of wild pandas captured by an infrared camera, in which an adult panda is sitting on the ground and eating bamboo leisurely.
According to the staff members, this wild panda eats
Fargesia denudata, which mainly grows between 2,100 meters and 3,100 meters above sea level.
In recent years, with the continuous improvement of the ecological environment in the reserve, wild pandas have often appeared in the camera, but it is rare to see such a clear, smooth and complete video as the one in which the scene of pandas having their meals is caught so clearly.
Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab)
two very rare forms of non-Hodgkin lymphoma will not have access to
an innovative systemic treatment following NICE s decision to not recommend mogamulizumab for routine use in the NHS
. Kyowa Kirin is disappointed by this decision but remains committed to finding a resolution with NICE.
The National Institute for Health and Care Excellence (NICE) today published its final appraisal document (FAD) for POTELIGEO
(mogamulizumab) announcing that POTELIGEO will not be made available on the NHS
(1)
LAS VEGAS, March 4, 2021 /PRNewswire/ Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100?000 per year.
However, these cases are not confined to one or the other particular geography, but are disproportionately spread across the world. Many rare human cancers are not curable, and have limited number of treatment options. Rare cancers are more difficult to diagnose and are often misdiagnosed. Rarity of the cancers further complicates the running of clinical trials. Lack of clinical expertise, research, and funding are other barriers in the Rare cancer market.